Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results
The recently published Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) provides interesting evidence for the use of statins in hypertensive patients with average cholesterol concentrations and other cardiovascular risk factors. The clinical benefit of atorvastatin in...
Gespeichert in:
| Veröffentlicht in: | Drugs (Basel) 2004, Vol.64 (Supplement 2), p.61-67 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 67 |
|---|---|
| container_issue | Supplement 2 |
| container_start_page | 61 |
| container_title | Drugs (Basel) |
| container_volume | 64 |
| creator | BLANCO-COLIO, Luis Miguel OSENDE, Julio I MARTIN-VENTURA, Jose Luis TUNON, José EGIDO, Jesus |
| description | The recently published Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) provides interesting evidence for the use of statins in hypertensive patients with average cholesterol concentrations and other cardiovascular risk factors. The clinical benefit of atorvastatin in these patients is probably explained by both lipid-dependent and lipid-independent effects of the drug. Many of these effects are related to inhibition of the synthesis of isoprenoid, which serves as lipid attachment for a variety of proteins implicated in intracellular signalling. These proteins have an important role in cell growth, actin cytoskeleton organisation, membrane trafficking, gene expression, cell proliferation/migration and programmed cell death. In this article we summarise the different effects of statins inrelation to the results observed in the ASCOT-LLA study. |
| doi_str_mv | 10.2165/00003495-200464002-00006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67277626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67277626</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-3da197eff4fa0e2192b6c379998739b81515685de4294ba59d2f09c29b3b06103</originalsourceid><addsrcrecordid>eNpFkF9LwzAUxYMobk6_guRF36JJ2iS9vo3hPyhM2ATfStqmrNK1NUnFfXtTN_W-XO65v3MTDkKY0RvOpLiloaIYBOGUxjKmlJNRkkdoypgCwkDQYzSllHEipVQTdObc-ziCgFM0YUJJkQCboreV175uHa5bvNn1xnrTuvrT4D7IpvXuDr90QfO1brD56hvdhkUXDFVnsd8YPF8tlmuSpnPs_FDusDVuaLw7RyeVbpy5OPQZen24Xy-eSLp8fF7MU1LwJPEkKjUDZaoqrjQ1nAHPZREpAEhUBHnCBBMyEaWJOcS5FlDyikLBIY9yKhmNZuh6f7e33cdgnM-2tStMEz5qusFlUnGlJJcBTPZgYTvnrKmy3tZbbXcZo9mYavabavaX6o80Wi8Pbwz51pT_xkOMAbg6ANoVuqmsbova_XMyimMlkugb0NR-8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67277626</pqid></control><display><type>article</type><title>Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>BLANCO-COLIO, Luis Miguel ; OSENDE, Julio I ; MARTIN-VENTURA, Jose Luis ; TUNON, José ; EGIDO, Jesus</creator><creatorcontrib>BLANCO-COLIO, Luis Miguel ; OSENDE, Julio I ; MARTIN-VENTURA, Jose Luis ; TUNON, José ; EGIDO, Jesus</creatorcontrib><description>The recently published Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) provides interesting evidence for the use of statins in hypertensive patients with average cholesterol concentrations and other cardiovascular risk factors. The clinical benefit of atorvastatin in these patients is probably explained by both lipid-dependent and lipid-independent effects of the drug. Many of these effects are related to inhibition of the synthesis of isoprenoid, which serves as lipid attachment for a variety of proteins implicated in intracellular signalling. These proteins have an important role in cell growth, actin cytoskeleton organisation, membrane trafficking, gene expression, cell proliferation/migration and programmed cell death. In this article we summarise the different effects of statins inrelation to the results observed in the ASCOT-LLA study.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.2165/00003495-200464002-00006</identifier><identifier>PMID: 15765891</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject>Biological and medical sciences ; Cholesterol - blood ; Endothelium, Vascular - pathology ; Endothelium, Vascular - physiopathology ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypertension - blood ; Hypertension - complications ; Hypertension - drug therapy ; Hypertension - pathology ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Drugs (Basel), 2004, Vol.64 (Supplement 2), p.61-67</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c288t-3da197eff4fa0e2192b6c379998739b81515685de4294ba59d2f09c29b3b06103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,777,781,786,787,4010,4036,4037,23911,23912,25121,27904,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16344758$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15765891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BLANCO-COLIO, Luis Miguel</creatorcontrib><creatorcontrib>OSENDE, Julio I</creatorcontrib><creatorcontrib>MARTIN-VENTURA, Jose Luis</creatorcontrib><creatorcontrib>TUNON, José</creatorcontrib><creatorcontrib>EGIDO, Jesus</creatorcontrib><title>Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results</title><title>Drugs (Basel)</title><addtitle>Drugs</addtitle><description>The recently published Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) provides interesting evidence for the use of statins in hypertensive patients with average cholesterol concentrations and other cardiovascular risk factors. The clinical benefit of atorvastatin in these patients is probably explained by both lipid-dependent and lipid-independent effects of the drug. Many of these effects are related to inhibition of the synthesis of isoprenoid, which serves as lipid attachment for a variety of proteins implicated in intracellular signalling. These proteins have an important role in cell growth, actin cytoskeleton organisation, membrane trafficking, gene expression, cell proliferation/migration and programmed cell death. In this article we summarise the different effects of statins inrelation to the results observed in the ASCOT-LLA study.</description><subject>Biological and medical sciences</subject><subject>Cholesterol - blood</subject><subject>Endothelium, Vascular - pathology</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypertension - blood</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - pathology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkF9LwzAUxYMobk6_guRF36JJ2iS9vo3hPyhM2ATfStqmrNK1NUnFfXtTN_W-XO65v3MTDkKY0RvOpLiloaIYBOGUxjKmlJNRkkdoypgCwkDQYzSllHEipVQTdObc-ziCgFM0YUJJkQCboreV175uHa5bvNn1xnrTuvrT4D7IpvXuDr90QfO1brD56hvdhkUXDFVnsd8YPF8tlmuSpnPs_FDusDVuaLw7RyeVbpy5OPQZen24Xy-eSLp8fF7MU1LwJPEkKjUDZaoqrjQ1nAHPZREpAEhUBHnCBBMyEaWJOcS5FlDyikLBIY9yKhmNZuh6f7e33cdgnM-2tStMEz5qusFlUnGlJJcBTPZgYTvnrKmy3tZbbXcZo9mYavabavaX6o80Wi8Pbwz51pT_xkOMAbg6ANoVuqmsbova_XMyimMlkugb0NR-8w</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>BLANCO-COLIO, Luis Miguel</creator><creator>OSENDE, Julio I</creator><creator>MARTIN-VENTURA, Jose Luis</creator><creator>TUNON, José</creator><creator>EGIDO, Jesus</creator><general>Adis International</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results</title><author>BLANCO-COLIO, Luis Miguel ; OSENDE, Julio I ; MARTIN-VENTURA, Jose Luis ; TUNON, José ; EGIDO, Jesus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-3da197eff4fa0e2192b6c379998739b81515685de4294ba59d2f09c29b3b06103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Cholesterol - blood</topic><topic>Endothelium, Vascular - pathology</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypertension - blood</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - pathology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BLANCO-COLIO, Luis Miguel</creatorcontrib><creatorcontrib>OSENDE, Julio I</creatorcontrib><creatorcontrib>MARTIN-VENTURA, Jose Luis</creatorcontrib><creatorcontrib>TUNON, José</creatorcontrib><creatorcontrib>EGIDO, Jesus</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BLANCO-COLIO, Luis Miguel</au><au>OSENDE, Julio I</au><au>MARTIN-VENTURA, Jose Luis</au><au>TUNON, José</au><au>EGIDO, Jesus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results</atitle><jtitle>Drugs (Basel)</jtitle><addtitle>Drugs</addtitle><date>2004</date><risdate>2004</risdate><volume>64</volume><issue>Supplement 2</issue><spage>61</spage><epage>67</epage><pages>61-67</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><coden>DRUGAY</coden><abstract>The recently published Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) provides interesting evidence for the use of statins in hypertensive patients with average cholesterol concentrations and other cardiovascular risk factors. The clinical benefit of atorvastatin in these patients is probably explained by both lipid-dependent and lipid-independent effects of the drug. Many of these effects are related to inhibition of the synthesis of isoprenoid, which serves as lipid attachment for a variety of proteins implicated in intracellular signalling. These proteins have an important role in cell growth, actin cytoskeleton organisation, membrane trafficking, gene expression, cell proliferation/migration and programmed cell death. In this article we summarise the different effects of statins inrelation to the results observed in the ASCOT-LLA study.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>15765891</pmid><doi>10.2165/00003495-200464002-00006</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (Basel), 2004, Vol.64 (Supplement 2), p.61-67 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67277626 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Biological and medical sciences Cholesterol - blood Endothelium, Vascular - pathology Endothelium, Vascular - physiopathology General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypertension - blood Hypertension - complications Hypertension - drug therapy Hypertension - pathology Medical sciences Pharmacology. Drug treatments |
| title | Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T06%3A16%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statins%20in%20hypertensive%20patients:%20Potential%20explanations%20for%20the%20ASCOT-LLA%20study%20results&rft.jtitle=Drugs%20(Basel)&rft.au=BLANCO-COLIO,%20Luis%20Miguel&rft.date=2004&rft.volume=64&rft.issue=Supplement%202&rft.spage=61&rft.epage=67&rft.pages=61-67&rft.issn=0012-6667&rft.eissn=1179-1950&rft.coden=DRUGAY&rft_id=info:doi/10.2165/00003495-200464002-00006&rft_dat=%3Cproquest_cross%3E67277626%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67277626&rft_id=info:pmid/15765891&rfr_iscdi=true |